Increased C-reactive Protein in ACE-inhibitor-induced Angioedema

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2005 Jan 29

PMID 15676047

Citations 16

Authors

M Bas

T K Hoffmann

H Bier

G Kojda

Affiliations

Soon will be listed here.

Abstract

Aims: This study was designed to identify new factors which may contribute to angiotensin-converting-enzyme-inhibitor (ACEI)-induced angioedema.

Methods: In a retrospective cohort study we examined 25 patients who used an ACEI and presented at our emergency room with acute angioedema as well as 18 patients with unknown cause of angioedema and a total of 21 patients on ACEI-therapy without previous angioedema. We measured markers of inflammation such as acute-phase proteins (C-reactive protein, fibrinogen), leukocyte count and body temperature.

Results: The mean interval between initiation of ACEI treatment and first manifestation of angioedema was 35.8 +/- 5.3 months. During symptomatic angioedema, mean plasma levels of C-reactive protein and fibrinogen were significantly increased by 7.3-fold and 1.5-fold, respectively, while leukocyte count and body temperature were normal. These changes disappeared after successful treatment of angioedema and were not found in patients with angioedema of unknown cause and those receiving ACEI without having experienced angioedema.

Conclusion: Our findings demonstrate for the first time that ACEI-induced angioedema is associated with strongly increased plasma levels of CRP. We suggest that CRP is involved in the pathophysiology of ACEI-induced angioedema.

Citing Articles

Acquired Angioedema Post COVID-19 Infection: Can SARS-Cov-2 Induce Angioedema?.

Rios Rodriguez M, Singh J, Nwakudu K, Feely S, Khaliq A, Manna D Cureus. 2024; 16(10):e70951.

PMID: 39502969 PMC: 11537483. DOI: 10.7759/cureus.70951.

Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema.

Gil-Serrano J, Labrador-Horrillo M, Galvan-Blasco P, Sala-Cunill A, Bigas P, Pereira-Gonzalez J Front Immunol. 2024; 15:1400526.

PMID: 38953032 PMC: 11215006. DOI: 10.3389/fimmu.2024.1400526.

Correlation between anti-hypertensive drugs and disease progression among moderate, severe, and critically ill COVID-19 patients in the second referral hospital in Surabaya: A retrospective cohort study.

Suryantoro S, Thaha M, Hayati M, Yusuf M, Pikir B, Susilo H F1000Res. 2023; 10:393.

PMID: 34912542 PMC: 8593622. DOI: 10.12688/f1000research.51785.3.

Tongue protrusion as the presenting symptom of parapharyngeal abscess.

Visclosky T, Tomlinson S, Bohm L, Hashikawa A J Am Coll Emerg Physicians Open. 2021; 2(1):e12336.

PMID: 33521787 PMC: 7819265. DOI: 10.1002/emp2.12336.

Angioedema, ACE inhibitor and COVID-19.

Grewal E, Sutarjono B, Mohammed I BMJ Case Rep. 2020; 13(9).

PMID: 32912894 PMC: 7482445. DOI: 10.1136/bcr-2020-237888.

References

Di Napoli M, Papa F . Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke. 2003; 34(12):2922-9. DOI: 10.1161/01.STR.0000099124.84425.BB. View

AGOSTONI A, Cicardi M . Drug-induced angioedema without urticaria. Drug Saf. 2001; 24(8):599-606. DOI: 10.2165/00002018-200124080-00004. View

Liu Y, Yang X, Shesely E, Sankey S, Carretero O . Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure. J Am Coll Cardiol. 2004; 43(8):1473-80. DOI: 10.1016/j.jacc.2003.11.044. View

Ajayi A, Oyewo E, Ladipo G, Akinsola A . Enalapril and hydrochlorothiazide in hypertensive Africans. Eur J Clin Pharmacol. 1989; 36(3):229-34. DOI: 10.1007/BF00558152. View

Hedner T, Samuelsson O, Lunde H, Lindholm L, Andren L, Wiholm B . Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1992; 304(6832):941-6. PMC: 1882283. DOI: 10.1136/bmj.304.6832.941. View

Chen H, Liao W . Differential acute-phase response of rat kininogen genes involves type I and type II interleukin-6 response elements. J Biol Chem. 1993; 268(34):25311-9. View

Brown N, Ray W, Snowden M, Griffin M . Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996; 60(1):8-13. DOI: 10.1016/S0009-9236(96)90161-7. View

Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C . Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336(14):973-9. DOI: 10.1056/NEJM199704033361401. View

Liu Y, Yang X, Sharov V, Nass O, Sabbah H, Peterson E . Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997; 99(8):1926-35. PMC: 508017. DOI: 10.1172/JCI119360. View

10.

LeFebvre J, Murphey L, Hartert T, Jiao Shan R, Simmons W, Brown N . Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension. 2002; 39(2 Pt 2):460-4. DOI: 10.1161/hy0202.103054. View

11.

Howes L, Tran D . Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?. Drug Saf. 2002; 25(2):73-6. DOI: 10.2165/00002018-200225020-00001. View

12.

Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A . Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 2002; 359(9323):2088-9. DOI: 10.1016/S0140-6736(02)08914-6. View

13.

Nussberger J, Cugno M, Cicardi M . Bradykinin-mediated angioedema. N Engl J Med. 2002; 347(8):621-2. DOI: 10.1056/NEJM200208223470820. View

14.

Molinaro G, Adam A, Lepage Y, Hammerschmidt D, Koenigbauer U, Eastlund T . Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg9-bradykinin after contact activation. Transfusion. 2002; 42(11):1458-65. DOI: 10.1046/j.1537-2995.2002.00196.x. View

15.

Ridker P, Rifai N, Rose L, Buring J, Cook N . Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347(20):1557-65. DOI: 10.1056/NEJMoa021993. View

16.

Wang C, Li S, Weisel R, Fedak P, Dumont A, Szmitko P . C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003; 107(13):1783-90. DOI: 10.1161/01.CIR.0000061916.95736.E5. View

17.

Du Clos T . C-reactive protein as a regulator of autoimmunity and inflammation. Arthritis Rheum. 2003; 48(6):1475-7. DOI: 10.1002/art.11025. View

18.

Pfeffer M, McMurray J, Velazquez E, Rouleau J, Kober L, Maggioni A . Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20):1893-906. DOI: 10.1056/NEJMoa032292. View

19.

Brown N, Snowden M, Griffin M . Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. JAMA. 1997; 278(3):232-3. DOI: 10.1001/jama.278.3.232. View

20.

Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, AGOSTONI A . Plasma bradykinin in angio-oedema. Lancet. 1998; 351(9117):1693-7. DOI: 10.1016/S0140-6736(97)09137-X. View